Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy

19 Jan 2023

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
šŸ—³ļø Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.